Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hallett, M.
Right arrow Articles by Stacy, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hallett, M.
Right arrow Articles by Stacy, M.
Related Collections
Right arrow Botulinum toxin
Right arrow Eyelids
Right arrow All clinical neurophysiology
Right arrow Blepharospasm
Right arrow Genetic linkage
NEUROLOGY 2008;71:1275-1282
© 2008 American Academy of Neurology
Views & Reviews

Update on blepharospasm

Report from the BEBRF International Workshop

Mark Hallett, MD, Craig Evinger, PhD, Joseph Jankovic, MD and Mark Stacy, MD

From the Human Motor Control Section (M.H.), NINDS, NIH, Bethesda, MD; Department of Neurobiology & Behavior (C.E.), SUNY Stony Brook, NY; Parkinson’s Disease Center and Movement Disorders Clinic (J.J.), Department of Neurology, Baylor College of Medicine, Houston, TX; and Neurology Department (M.S.), Duke University Medical Center, Durham, NC.

Address correspondence and reprint requests to Dr. Mark Hallett, Human Motor Control Section, NINDS, NIH, Building 10, Room 5N226, 10 Center Drive MSC 1428, Bethesda, MD 20892-1428 hallettm{at}ninds.nih.gov

This review updates understanding and research on blepharospasm, a subtype of focal dystonia. Topics covered include clinical aspects, pathology, pathophysiology, animal models, dry eye, photophobia, epidemiology, genetics, and treatment. Blepharospasm should be differentiated from apraxia of eyelid opening. New insights into pathology and pathophysiology are derived from different types of imaging, including magnetic resonance studies. Physiologic studies indicate increased plasticity and trigeminal sensitization. While botulinum neurotoxin injections are the mainstay of therapy, other therapies are on the horizon.

Abbreviations: BFMDRS = Burke-Fahn-Marsden dystonia rating scale; BoNT = botulinum neurotoxin; DBS = deep brain stimulation; DTI = diffusion tensor imaging; FDG = 18fluorodeoxyglucose; VBM = voxel-based morphometry.

Supported by the NIH Intramural Program (M.H.) and NIH grant EY07391 (Control of eyelids in normal and pathological states) (C.E.). Dr. Jankovic has received research grants from the following: Advanced Neuromodulation Systems; Allergan, Inc.; Boehringer-Ingelheim; Ceregene, Inc.; EMD; Eisai; Ipsen Limited; Huntington’s Disease Society of America; Kyowa Pharmaceuticals; Medtronic; Merz Pharmaceuticals; National Institutes of Health; National Parkinson Foundation; Novartis; Ortho-McNeil; Parkinson Study Group; Prestwick Pharmaceuticals; Schering; Schwarz Pharma/UCB; Teva.

Disclosure: Author disclosures are provided at the end of the article.

Received January 14, 2008. Accepted in final form June 3, 2008.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by AAN Enterprises, Inc.